Table 4 Patients on a pathway of non-curative intent.

Whole cohort

n = 813

Recommended Palliative Therapy

223 (57.3%)

201 (47.4%)

0.004

Received palliative therapy

103 (26.5%)

87 (20.5%)

0.045

Recommended best supportive care

166 (42.7%)

223 (52.6%)

Received best supportive care

286 (73.5%)

337 (79.5%)

Received palliative chemotherapy

96 (24.7%)

80 (18.9%)

0.044

Received palliative radiotherapy

13 (3.3%)

15 (3.5%)

0.878

Palliative surgery

4 (1.7%)

1 (0.4%)

0.217

Reason for non-curative pathway selection

Metastatic disease

254 (65.2%)

251 (59.1%)

0.363

Locally advanced disease

76 (19.5%)

88 (20.7%)

Potentially resectable but not offered surgery due to:

-Performance status

39 (10.0%)

55 (12.9%)

-Patient choice

8 (2.0%)

14 (3.3%)

-Unknown

12 (3.0%)

16 (3.7%)

Cohort that received palliative chemotherapy only

n = 176

n = 96

n = 80

FOLFIRINOX

29 (30.2%)

38 (47.5%)

0.088

Gem/Cap

15 (15.6%)

13 (16.3%)

Gem/Abraxane

21 (21.9%)

10 (12.5%)

Gemcitabine or capecitabine

27 (28.1%)

14 (17.5%)

Other

4 (4.2%)

5 (6.3%)

Completed full allocation of cycles

37 (38.5%)

33 (41.3%)

0.625

Median time to chemotherapy days (IQR)

52 (42.3–73.3)

49 (41.3–75.5)

0.699

2nd line palliative chemotherapy received

12 (12.5%)

10 (12.5%)

0.954

Cohort that received no palliative therapy, after recommendation.

n = 623

n = 286

n = 337

Frailty

130 (45.4%)

164 (48.6%)

0.277

Patient choice

58 (20.2%)

63 (18.6%)

Recurrence/progression

83 (29%)

89 (26.4%)

COVID

0 (0%)

8 (2.3%)

Unknown

15 (5.2%)

13 (3.8%)